B4-02: Incidence of occupational lung cancer in Tehran-Iran  by Kolahi, Ali A. & Mosavi-Jarrahi, Alireza
Copyright © 2007 by the International Association for the Study of Lung Cancer S343
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
demonstrate radiosensitization following molecular inhibition of EGFR 
signaling. 
Methods: We report a phase II trial testing the combination of C225 
with CRT in unresectable stage III NSCLC with a planned sample 
size of 84 PTS. Eligibility criteria included Zubrod performance status 
(PS) ≤ 1, weight loss ≤ 5% over past 3 months, FEV1 ≥ 1.2 l, adequate 
hematologic, hepatic, and renal function. PTS received an initial dose 
of C225 (400 mg/m2) on day 1 of week 1, then weekly doses of C225 
(250 mg/m2) until completion of therapy (weeks 2 – 17). During week 
2, PTS started CRT (63 Gy/35 fractions) with weekly carboplatin (C) 
AUC 2 and paclitaxel (P) 45 mg/m2 x 6 doses followed by C (AUC 6) 
and P (200 mg/m2) x 2 cycles (weeks 12-17). Interim monitoring for 
severe (grade ≥ 3) or excessive non-hematologic toxicities occurred 
after PTS had been treated and followed for at least 90 days after RT. 
Primary endpoints include safety and compliance of concurrent C225 
and CRT. 
Results: 93 PTS were enrolled with 87 evaluable PTS. PTS character-
istics: 57% male, median age 64 years (range 42-85), 47% PS 0, 46% 
stage IIIA. Median follow-up is 17.6 months. Response rate is 62% 
(n=54) and 18 month overall survival (OS) is 54.7%(# at risk=39). 
Adverse events related to treatment include 20%(n=17) of PTS with 
grade 4 hematologic toxicities and 7 PTS who had grade 3 esophagi-
tis. There was 1 infection related death, 1 death NOS, and 3 PTS who 
died of pulmonary complications (adult respiratory distress syndrome, 
pneumonitis, and hypoxia). 
Conclusions: The combination of C225 with CRT is feasible. Further 
study will be needed to determine whether the addition C225 to CRT 
enhances toxicity or efﬁcacy. Complete compliance and toxicity data 
along with median survival will be reported.
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Background: Smoking is the second major cause of death in the world. 
If current smoking patterns continue, it will cause 10 million deaths/
year by 2020. The aim of the present study is to estimate the mortality 
and DALYs (disability adjusted life years) directly related to smok-
ing in Portugal focused on the most frequent diseases associated with 
smoking, as well as the mortality and DALYs potential reduction with 
smoking cessation.
Methods: The methodology used is that of the WHO and the World 
Bank. The process involves two steps: identiﬁcation of diseases closely 
associated with smoking coded in the International Classiﬁcation of 
Diseases, and determining the quantitative relation between smok-
ing and the identiﬁed diseases using the epidemiological concepts of 
relative risk and population attributable risk. As the risk for ex-smok-
ers will never be the same as nonsmokers we determined the burden 
related to mortality if smoking ceased at present.
Results: The investigation of burden of disease from mortality at-
tributable to smoking was based on analysis of data from the National 
Statistics Institute for the year 2004. There were 6.565 DALYs lost per 
100.000. The group of diseases related to smoking is responsible for 
50% of the deaths and 39% of the DALYs. Twelve percent of the total 
disease burden due to mortality and DALYs is attributable to smoking, 
being higher for men (16% of DALYs) than for women (4%). If smok-
ing was abandoned, the burden of disease would be reduced by 53% 
(54% in men; 65% in women).
Conclusions: Twelve percent of the overall disease burden and mortal-
ity is attributable to smoking. The health gains obtained by reducing 
tobacco consumption could reach 50%. This highlights the importance 
of smoking cessation as a priority in health policies.
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Background: Occupational carcinogens occupy a special place among 
the different classes of human carcinogens. The aim of this study was 
to estimate the fraction of lung cancer incidence attributed to occupa-
tional exposures to Silica, Cadmium, Nickel, Arsenic, Chromium, Die-
sel Fumes, Beryllium, and Asbestos (the best established lung cancer 
carcinogens in the workplace).
Methods: Exposure to each of the mentioned carcinogens at national 
level was estimated using workforce data estimated by the population 
census 1995 and obtained from the ILO. The prevalence of exposure 
for each industry/ carcinogens was estimated using exposure data from 
the CAREX database (CAREX is an international information system 
on occupational exposure to known and suspected carcinogens kept and 
maintained by EU). The magnitude of relative risk of lung cancer for 
each carcinogen of interest was estimated from local and international 
literatures. The Levin modiﬁed population attributable risk (incidence) 
fraction was utilized to estimate the fraction of lung cancer incidence as 
estimated by the Tehran Population Based Cancer Registry that could 
be attributed to workplace exposure of carcinogens of interest. 
Results: The crude incidence of lung cancer was 10.4 and 5 per 
100.000 populations of male and female, respectively. Total workforce 
according to the 1995 census was 13165489 of which 12488020 were 
male and 677469 were female. Agricultural sectors with 25% hold the 
most frequent number of workforce and electrical related sector with 
0.01% hold the least frequent number of workforce. After applying the 
CAREX exposure estimate to each sector, the proportion of male work-
ers exposed to lung carcinogen was 0.08 and this ﬁgure was 0.02 for 
females. Estimating a relative risk of 1.9 for high exposure and 1.5 for 
low exposure and employing The Levin modiﬁed formula, the fraction 
of lung cancer attributed to carcinogens in the workplace among female 
was 0.015 with a 95% CI of (0.012 to 0.019) and this ﬁgures were 0.12 
with 95%CI of (0.10 to 0.15) for male. These fractions correspond to an 
estimated incidence of 1.12 cases lung cancer per 100,000 populations 
among male and 0.8 cases of lung cancer among 100,000 population of 
female. Table 3 Show Proportion of workers exposed to lung carcino-
gens, by industry based on the CAREX estimates.
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Carcino-
gens
Agricul-
ture
Mining
Manu-
facturing
Electrical
Construc-
tion
Trade
Trans-
porta-
tion
Services
Silica 0.004 0.230 0.023 0.014 0.189 0.000 0.005 0.001
Cadmium 0.000 0.000 0.005 0.003 0.003 0.000 0.001 0.000
Nickel 0.000 0.020 0.017 0.004 0.000 0.000 0.000 0.000
Arsenic 0.001 0.001 0.004 0.001 0.001 0.000 0.000 0.000
Chro-
mium 0.000 0.003 0.021 0.004 0.002 0.000 0.004 0.002
Diesel 
Fumes 0.006 0.220 0.011 0.034 0.058 0.005 0.134 0.009
Beryllium 0.000 0.001 0.002 0.001 0.000 0.000 0.000 0.000
Asbestos 0.012 0.102 0.006 0.017 0.052 0.003 0.007 0.003
Table 3: Proportion of workers exposed to lung carcinogens, by industry 
based on the CAREX estimates (FIOH, 1998).
Conclusion: The incidence of lung cancer due to occupational expo-
sure is low in our country and as it is the case for other populations, 
there is more lung cancer due to occupational exposure among male 
compared to female. 
B4-03 Prevention & Early Detection + Epidemiology, Tue, 13:45 - 15:30
Small cell cancer with an unknown primary site had a better 
prognosis than advanced small cell lung cancer
Bishop, James F.1 Tracey, Elizabeth2 Glass, Parisa2 
1 Cancer Institute NSW, Alexandria, NSW, Australia 2 Cancer Institute 
NSW, Sydney, NSW, Australia 
Background: The aim of this study is to compare the clinical outcomes 
of patients diagnosed with small cell cancer of unknown primary 
(CUP) origin to those diagnosed with metastatic small cell cancer of 
known origin. 
Methods: All persons diagnosed with cancer in New South Wales, 
Australia, from 1980 to 2004 were studied using a population based 
cancer registry. Patients classiﬁed as small cell CUP were documented 
and survival outcome compared to those with initial small cell meta-
static presentations with a known primary site, for the same period. 
This register collects degrees of cancer spread at diagnosis as localised, 
regional and metastatic but does not use a clinical staging system. 
Results: There were 65,239 histologically or cytologically conﬁrmed 
metastatic cancers identiﬁed at initial presentation of which 14,502 
were CUP. Further classiﬁcation into histological subsets showed that 
3,713 (5.7%) of metastatic presentation were small cell cancer. Of 
those diagnosed with small cell histology, 516 (14%) were CUP and 
the rest were classiﬁed as advanced small cell with a known primary 
site. CUP had a signiﬁcantly higher proportion of females and older 
individuals compared to metastatic cancer of known primary site. 
Logistic regression analysis controlling for age and sex revealed that 
small cell CUP had signiﬁcantly better survival than advanced small 
cell cancer of the lung and other primary sites (hazard ratio 0.77, 95% 
conﬁdence intervals 0.71-0.85, p<0.0001). At 6 years 15% of small cell 
CUP remained alive compared to only 4% for other metastatic small 
cell patients with a known primary site almost all from the lung. 
Conclusions: Some histological subsets of CUP have a better progno-
sis than metastatic cancer at presentation. Small cell CUP has signiﬁ-
cantly better long term survival than metastatic small cell cancer of 
known primary site predominantly from the lung which suggests a need 
for genetic proﬁling and more speciﬁc treatment strategies. 
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Background: With increase of peripherally located lung cancers, clini-
cal need for percutaneous needle biopsy become high but could cause 
chest wall inoculation of cancer cells. We evaluated the expression of 
melanoma antigen gene(MAGE) A1-6 common primers from broncho-
scopic washing ﬂuid whether it could replace needle biopsy.
Materials and Methods: Twenty-nine patients with bronchoscopi-
cally invisible peripheral lung nodules were studied. Tumor locations 
were categorized by 5.8 mm ﬁberoptic bronchoscopy(Olympus, Tokyo, 
Japan). Bronchoscopic washing specimens were collected by instilla-
tion of 20ml normal saline to the tumor bearing segment and retrieved. 
Samples were divided, one for MAGE RT-PCR and the other for con-
ventional cytology. After surgery, 19 patients were diagnosed as lung 
cancer(11 squamous cell carcinoma and 8 adenocarcinoma) and 10 
were benign lung diseases. For MAGE specimens, RNA preservation 
solutions were added immediately and blindly sent to the laboratory. 
RNA extraction was performed using mRNA extraction kit and MAGE 
and GAPD were ampliﬁed using MAGE A1-6 common primers and 
sequence speciﬁc primer. We evaluated the positive rates according to 
the cell types and T stages, and compared the results with conventional 
cytology ﬁndings.
Results: From bronchial washes, positive rates of MAGE and cytol-
ogy tests showed 63.2 and 21.4% in cancer group and 10.0 and 0% in 
benign diseases group. According to cell types, positive rates of MAGE 
and cytology test were 63.6 and 28.6 % in squamous cell carcinoma, 
62.5 and 14.3 % in adenocarcinoma. According to T stages, positive 
rates of MAGE and cytology test were 71.4 and 20.0 % in T1 stage 
(N=7), 44.4 and 16.7 % in T2 stage (N=9), 100 and 33.3 % in T4 stage 
(N=3). For 11 patients with tumor size smaller than 3cm, positive rate 
of MAGE and cytology were 54.5% and 9.1%. 
Conclusions: Compared with conventional cytology test, MAGE 
A1-6 RT-PCR showed high detection rates in the bronchial washes of 
peripheral lung cancer patients. This method is simple and robust, thus 
it could be effectively utilized as a peripheral lung cancer detection tool 
in the clinical laboratory.
